Study of entinostat in ER negative breast cancer

• Research type

  Research Study

• Full title

  A Phase II, Two Centre, Open Label Study of the Effects of Entinostat on Expression of Biomarkers in Subjects with Newly Diagnosed Oestrogen Receptor Negative Breast Cancer

• IRAS ID

  16518

• Contact name

  J Michael Dixon

• Sponsor organisation

  University of Edinburgh

• Eudract number

  2010-018899-25

• Research summary

  This is a study where patients whose cancers do not have evidence of hormone responsiveness will be given a single dose of the drug entinostat 36-48 hours before operation. The aim is to see if the drug can change the cancer to a hormone responsive type by switching on hormone receptors.

• REC name

  Scotland A REC

• REC reference

  10/MRE00/31

• Date of REC Opinion

  16 Jun 2010

• REC opinion

  Further Information Favourable Opinion